Intoxication by Colchicine in a compounded pharmaceutical formulation
Vol. 67 No. 3 (2008), CASE REPORT
Vol. 67 No. 3 (2008)

Intoxication by Colchicine in a compounded pharmaceutical formulation

CASE REPORT
https://doi.org/10.53393/rial.2008.67.32772
Published 2008-08-01
Helena Miyoco Yano
Instituto Adolfo Lutz, Divisão de Bromatologia e Química, Serviço de Medicamentos, São Paulo, SP
Adriana Bugno
Instituto Adolfo Lutz, Centro de Medicamentos, Cosméticos e Saneantes, Núcleo de Ensaios Biológicos e de Segurança, São Paulo, SP
Mariângela Tirico Auricchio
Instituto Adolfo Lutz, Divisão de Bromatologia e Química, Serviço de Medicamentos, São Paulo, SP
PDF (Português (Brasil))

Keywords

colchicine
compounded pharmaceutical formulation
overdose

How to Cite

1.
Yano HM, Bugno A, Auricchio MT. Intoxication by Colchicine in a compounded pharmaceutical formulation. Rev Inst Adolfo Lutz [Internet]. 2008 Aug. 1 [cited 2024 Nov. 26];67(3):234-6. Available from: https://periodicos.saude.sp.gov.br/RIAL/article/view/32772
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The present work relate a case of overdose of colchicine in a capsules of compounded pharmaceutical formulation whose ingestion dose initiated a process of acute gastrointestinal haemorrhage leading the patient to death. Colchicine is a pharmacon of low therapeutical index drug, and the maximum recommended dose for gout treatment in adult is 2.5 mg at the first 24 hours. The remaining non- ingested capsules were analyzed by spectrophotometry, and colchicine amount was determined according to the Brazilian Pharmacopoeia, IV edition. The average dosage was of 47.36 mg, that is, about 20 times higher than the maximum recommended dose. The dosage mistake was evidenced in the medicament prescription, and also in consultation the professional responsible for prescribing the medicine on the part of operator who processed the colchicines formulation.
https://doi.org/10.53393/rial.2008.67.32772
PDF (Português (Brasil))

References

1. Korolkovas A, Burckhalter, JH Química Farmacêutica Rio de Janeiro: Guanabara Koogan, p. 181-217, 1982.

2. Insel PA. Analgesic-Antipyretic and Antiinflamatory Agents And Drug Employed In The Treatment Of Gout. In: Goodman & Gilman ́s the pharmacological basis of theurapeutics. 9ª ed., editores Hardman, JG eLimbird, LE. New York: McGraw-Hill, 1996, p. 617-57

3. Brasil, Leis e Decretos - RDC nº 232 de 17 de agosto de 2005 da Agência Nacional de Vigilância Sanitária do Ministério da Saúde. estabelece inclusão da substância COLCHICINA no anexo I – Substância de Baixo Índice Terapêutico. DOU de 18 de agosto de 2005. Disponível em http://e-legis.anvisa.gov.br/leisref/public/showAct.php?id=18248&word=. Acesso em 20 de fevereiro de 2008.

4. Yano HM, Auricchio MT. Digitoxina: superdosagem em medicamento manipulado. Rev Inst Adolfo Lutz. 2005;64:273-75.

5. ANVISA- Manipulação de Colchicina restrita após mortes de usuários. Disponível em http://www.anvisa.gov.br/DIVULGA/noticias/2005/180805_4.htm. Acesso em: 20 de fevereiro de 2008.

6. Gabriel PMKC, Gabriel MM, Escorsin Neto F, Lopes M. Colchicina: Intoxicação e Óbito, Relato de Caso. Visão Acadêmica. 2004;5:47-52.

7. Resolução RDC nº 67, de 08 de outubro de 2007.

8. British Pharmacopeia. London: The Stationary Office, 2004, p. 2319.

9. Farmacovigilância - Uso criterioso de colchicina. Pharmacia Brasileira.2006;X,56: 5.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2008 Instituto Adolfo Lutz Journal

Downloads

Download data is not yet available.